Zur Kurzanzeige

2022-06-03Zeitschriftenartikel
Prevalence of Chlamydia trachomatis in the general population in Germany – a triangulation of data from two population-based health surveys and a laboratory sentinel system
dc.contributor.authorGassowski, Martyna
dc.contributor.authorPhoetko-Mueller, Christina
dc.contributor.authorSchlaud, Martin
dc.contributor.authorSailer, Andrea
dc.contributor.authorDehmel, Kerstin
dc.contributor.authorBremer, Viviane
dc.contributor.authorDudareva, Sandra
dc.contributor.authorJansen, Klaus
dc.contributor.authorClamydia trachomatis laboratory sentinel team
dc.date.accessioned2024-09-18T12:43:01Z
dc.date.available2024-09-18T12:43:01Z
dc.date.issued2022-06-03none
dc.identifier.other10.1186/s12889-022-13456-7
dc.identifier.urihttp://edoc.rki.de/176904/12196
dc.description.abstractBackground Chlamydia trachomatis (chlamydia) is a common, frequently asymptomatic, sexually transmitted infection. It can result in severe sequelae, such as ectopic pregnancy and infertility. In Germany, chlamydia is not notifiable. An opportunistic screening program for women < 25 years was introduced in 2008. The aim of this research was to triangulate different data sources to describe the epidemiological situation of chlamydia in Germany and to investigate whether the current target group of the chlamydia screening program aligns with these findings. Methods Urine specimens from participants from population-based health examination surveys of children (2014–17) and adults (2008–11) were tested for chlamydia, using nucleic acid amplification testing. These data were used to generate weighted chlamydia prevalence estimates by age group and sex. Data from a nationwide chlamydia laboratory sentinel system (2014–16) were used to calculate the positive proportion among individuals tested for chlamydia by age, sex and test reason. Results Using data from the population-based surveys, we found a chlamydia prevalence estimate of 2.8% (95% confidence interval (CI) 1.0–7.5%) among all 15- to 17-year-old girls and of 9.6% (95% CI 0.0–23) among those reporting to be sexually active. In adult women, we found the highest prevalence among 18- to 24-year-olds (all: 2.3%; 95% CI 1.0–5.3%; sexually active: 3.1%; 95% CI 1.3–7.0%). In adult men, we found the highest prevalence among 25- to 29-year-olds (all: 3.5%; 95% CI 1.6–7.7%; sexually active: 3.3%; 95% CI 1.3–7.8%). Data from the chlamydia laboratory sentinel showed the highest positive proportion among those opportunistically screened in 19-year-old women (6.1%; 95%- CI 5.9–6.4%), among those screened due to pregnancy in 15-year-old girls (10%; 95% CI 8.5–12%), and among those tested due to symptoms or a positive partner in 19-year-old women (10%; 95% CI 9.8–11%) and 19-year-old men (24%; 95% CI 22–26%). Conclusions Chlamydia seems to mainly affect adolescents and young adults in Germany, with similar overall prevalence in men and women, but with slightly different age distributions. Women at highest risk of chlamydia are covered by the current screening program but given the on-going discussions in high-income countries on cost-effectiveness and benefit-to-harm ratio of these programs, the program-aim needs reconsideration.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectchlamydia trachomatiseng
dc.subjectsexually transmitted infectionseng
dc.subjectscreeningeng
dc.subjectprevalenceeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titlePrevalence of Chlamydia trachomatis in the general population in Germany – a triangulation of data from two population-based health surveys and a laboratory sentinel systemnone
dc.typearticle
dc.identifier.urnurn:nbn:de:0257-176904/12196-7
dc.type.versionpublishedVersionnone
local.edoc.container-titleBMC Public Healthnone
local.edoc.container-issn1471-2458none
local.edoc.pages9none
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://bmcpublichealth.biomedcentral.com/none
local.edoc.container-publisher-nameSpringer Naturenone
local.edoc.container-volume22none
local.edoc.container-reportyear2022none
dc.description.versionPeer Reviewednone

Zur Kurzanzeige